Polyarteritis nodosa pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:
==Pathophysiology==
==Pathophysiology==
Polyarteritis nodosa is a disease of unknown cause that affects arteries, the blood vessels that carry oxygenated blood to organs and tissues. It occurs when certain immune cells attack the affected arteries.Inflammation starts in the vessel intima and results in [[fibrinoid necrosis]] by destroying the internal and external elastic lamina. Aneurysms and thrombi may develop at the site of lesions. One hypothesis is that this condition is caused by antibodies against HBV, via a [[Hypersensitivity#Type_3_-_immune_complex | type IIII hypersensitivity reaction]]. [[Hepatitis C]] associated polyarteritis nodosa is the most common type among the hepatitis C associated vasculitis and has a severe clinical presentation.<ref name="pmid20981809">{{cite journal |author=Saadoun D, Terrier B, Semoun O, ''et al.'' |title=Hepatitis C virus-associated polyarteritis nodosa |journal=Arthritis Care Res (Hoboken) |volume=63 |issue=3 |pages=427–35 |year=2011 |month=March |pmid=20981809 |doi=10.1002/acr.20381 |url=}}</ref>
Polyarteritis nodosa is a disease of unknown cause that affects arteries, the blood vessels that carry oxygenated blood to organs and tissues. It occurs when certain immune cells attack the affected arteries.Inflammation starts in the vessel intima and results in [[fibrinoid necrosis]] by destroying the internal and external elastic lamina. Aneurysms and thrombi may develop at the site of lesions. One hypothesis is that this condition is caused by antibodies against HBV, via a [[Hypersensitivity#Type_3_-_immune_complex | type IIII hypersensitivity reaction]]. [[Hepatitis C]] associated polyarteritis nodosa is the most common type among the hepatitis C associated vasculitis and has a severe clinical presentation.<ref name="pmid20981809">{{cite journal |author=Saadoun D, Terrier B, Semoun O, ''et al.'' |title=Hepatitis C virus-associated polyarteritis nodosa |journal=Arthritis Care Res (Hoboken) |volume=63 |issue=3 |pages=427–35 |year=2011 |month=March |pmid=20981809 |doi=10.1002/acr.20381 |url=}}</ref>
The pathogenesis of PAN remains unknown. However, the clinical responses to immunosuppressive therapy suggest that immunological mechanisms play an active pathogenic role. Due to inflammation of the medium to small sized vessels in PAN and the presence of impaired endothelial function, there could be direct endothelial cell activation and damage resulting from proinflammatory cytokines or antibodies (anti-endothelial cells antibodies). These anti-endothelial cells antibodies in turn stimulate greater production of cytokines and adhesion molecules potentiating the inflammation causing more damage to the vessels <ref name="pmid12525387">{{cite journal| author=Filer AD, Gardner-Medwin JM, Thambyrajah J, Raza K, Carruthers DM, Stevens RJ et al.| title=Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. | journal=Ann Rheum Dis | year= 2003 | volume= 62 | issue= 2 | pages= 162-7 | pmid=12525387 | doi= | pmc=1754444 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12525387  }} </ref>.


==References==
==References==

Revision as of 14:39, 3 November 2016

Polyarteritis nodosa Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polyarteritis nodosa from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiography

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polyarteritis nodosa pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polyarteritis nodosa pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polyarteritis nodosa pathophysiology

CDC on Polyarteritis nodosa pathophysiology

Polyarteritis nodosa pathophysiology in the news

Blogs on Polyarteritis nodosa pathophysiology

Directions to Hospitals Treating Polyarteritis nodosa

Risk calculators and risk factors for Polyarteritis nodosa pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]Cafer Zorkun, M.D., Ph.D. [4]; Haritha Machavarapu, M.B.B.S.

Overview

Pathophysiology

Polyarteritis nodosa is a disease of unknown cause that affects arteries, the blood vessels that carry oxygenated blood to organs and tissues. It occurs when certain immune cells attack the affected arteries.Inflammation starts in the vessel intima and results in fibrinoid necrosis by destroying the internal and external elastic lamina. Aneurysms and thrombi may develop at the site of lesions. One hypothesis is that this condition is caused by antibodies against HBV, via a type IIII hypersensitivity reaction. Hepatitis C associated polyarteritis nodosa is the most common type among the hepatitis C associated vasculitis and has a severe clinical presentation.[1]

The pathogenesis of PAN remains unknown. However, the clinical responses to immunosuppressive therapy suggest that immunological mechanisms play an active pathogenic role. Due to inflammation of the medium to small sized vessels in PAN and the presence of impaired endothelial function, there could be direct endothelial cell activation and damage resulting from proinflammatory cytokines or antibodies (anti-endothelial cells antibodies). These anti-endothelial cells antibodies in turn stimulate greater production of cytokines and adhesion molecules potentiating the inflammation causing more damage to the vessels [2].

References

  1. Saadoun D, Terrier B, Semoun O; et al. (2011). "Hepatitis C virus-associated polyarteritis nodosa". Arthritis Care Res (Hoboken). 63 (3): 427–35. doi:10.1002/acr.20381. PMID 20981809. Unknown parameter |month= ignored (help)
  2. Filer AD, Gardner-Medwin JM, Thambyrajah J, Raza K, Carruthers DM, Stevens RJ; et al. (2003). "Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa". Ann Rheum Dis. 62 (2): 162–7. PMC 1754444. PMID 12525387.

Template:WH Template:WS